Latest News

Arix Bioscience acquires 11% stake in Phamaxis Ltd.

Pharmaxis has two approved respiratory products: Bronchitol for cystic fibrosis and Aridol for the diagnosis and assessment of asthma.


by tg

An investor consortium led by British Arix Bioscience plc has put £13.4m into the Australian Pharmaxis Ltd, which develops fibrosis inhibitors based on its amine oxidase discovery platform.

London-based Arix Bioscience announced it has acquired an 11 % interest in Pharmaxis in a two tranche placement contributing £8m, while £5.4 came from existing investors such as BVF Partners L.P. The Pharmaxis Board approved the nomination of Arix’s Edward Rayner to join the Board in September 2018. 

Arix said it will use the proceeds to advance its proprietary Phase I lead programme, an orally administered anti-fibrotic Lysyl Oxidase-Like type 2 (LOXL2) inhibitor designed to block pathogenic fibrosis, which might create treatment options for diseases such as Non-alcoholic Steatohepatitis (NASH), Idiopathic Pulmonary Fibrosis (IPF), or heart and kidney fibrosis.  The company expects to finalise Phase I testing by Q3/2018. Furthermore, the company has two preclinical development programmes. In 2015, Pharmaxis' platform was validated through a licence deal with Boehringer Ingelheim – the candidate drug BI 1467335 (formerly known as  PXS-4728A) is in Phase II testing for NASH and Diabetic Retinopathy. 

Hydrogel fights wound infection and inflammation

The new gel mimics the body’s natural defenses to tackle both inflammation and bacterial infection – two major concerns for patients recovering from...

Merck and 4SC collaborate in immunooncology

Under the agreement, 4SC AG will sponsor clinical testing of a combination of its oral class I histone deacetylase (HDAC) blocker domatinostat (HDAC...

Astellas and Adaptimmune team up in CAR-T development

At J.P. Morgan conference, the British company announced that Astellas has agreed to co-develop and co-commercialize stem-cell derived allogeneic...

Valneva raises US$85m

Valneva said the transaction, led by US investors Deerfield Management Company and OrbiMed, included an initial US$60m fixed rate debt and flexible...

Novacyt inks contract on Covid-19 diagnostics

Novacyt SA ’s British molecular diagnostics division Primerdesign Ltd (Camberley) signed a global distribution agreement for its COVID-19 test with...

Commission relaunches circular economy action plan

A main goal of the new Circular Economy Action Plan as a major pillar of the European Green Deal, is sustainable growth. The new Action Plan...

PharmaMar/Jazz Pharmaceuticals get NDA priority for lung cancer drug

The PDUFA date was set for August 16, 2020 by the US Food and Drug Administration (FDA) for lurbinectedin as second-line treatment for patients with...